Gustavo Pesquin joined AskBio from Amneal Pharmaceuticals LLC, where he served as Chief Commercial Officer. Before that, Gustavo spent more than 10 years at Sanofi, a leading global pharmaceutical company, where he served in leadership roles of increasing responsibility, including North America Head for General Medicines as well as Global Head of the multi-billion dollar Diabetes and Cardiovascular Franchise. Prior to Sanofi, he held regional head, general manager, sales head, and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group. Pesquin earned an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and an undergraduate degree from Universidad Nacional de Cuyo in Argentina.

Stefan Oelrich has been a member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division, headquartered in Berlin, Germany, since November 2018. He is also responsible for the region Latin America. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held several positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Oelrich returned to the United States as Senior Vice President and General Manager of Women’s Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Oelrich became head of Sanofi’s Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Oelrich became head of Sanofi’s global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes & Cardiovascular on the Executive Committee of Sanofi. Since 2016, Oelrich has been a member of the Supervisory Board of the Berlin Institute of Health.

Wolfram Carius was the Head of Pharmaceuticals Product Supply from September 2016 to October 2020 (Chemicals, Pharma, Biotech, Devices) at Bayer AG. Wolfram is now Executive Vice President Pharmaceuticals, and he is a member of the Executive Leadership Team for Bayer Pharmaceuticals. He is based in Berlin, Germany. Prior to joining Bayer, Carius was a corporate senior vice president and member of the global leadership team at Sanofi Genzyme for two years. Before that, he worked for Boehringer Ingelheim from 1987 to the end of 2013, eventually becoming responsible for that company’s worldwide chemical, pharmaceutical, and biopharma production network. In his 30 years in the pharmaceutical industry he has worked in Asia, South America and Europe. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition for his long and exceptional service.

Dr. Rommel has served on the Askbio Board of Directors since 2021. He is the Executive Vice President, Global Head of Research & Development and Member of the Pharmaceuticals Leadership Team at Bayer, a role he has held since February 2021. From January 2014 to February 2021, Dr. Rommel served in various positions at Roche, culminating in his role as Senior Vice President, Global Head of Pharma Research and Early Development (pRED) Oncology. Prior to this, Dr. Rommel worked at Amgen where he held roles including Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech, from its inception to its acquisition by Takeda Pharmaceuticals. Dr. Rommel also contributes to the Board of Directors for BlueRock Therapeutics, Vividion Therapeutics, and CRISPR Therapeutics. He also serves on the Board of Trustees for the Max Planck Institute for Molecular Genetics. Dr. Rommel received his PhD in Molecular Oncology from the Max Planck Institute in Berlin, Germany, and the Institute of Medical Virology at the University of Zurich, Switzerland. In addition to his leadership roles, he lectured on biotechnology at the ETH Zurich, Switzerland, for several years. He has authored more than 70 publications, including papers in Science and Nature.

Dr. Mansuo Shannon joined AskBio in 2024 and serves as its Chief Scientific Officer (CSO). She is responsible for developing and implementing the company’s R&D strategy and leads all aspects of the discovery and development of AskBio’s gene therapy platform. Dr. Shannon also oversees the global teams charged with advancing that platform and provides scientific leadership to the CEO, Board of Directors, and company as a whole, in addition to being a key partner of the broader Bayer R&D leadership team and Bayer’s scientific community. Prior to joining AskBio, Dr. Shannon served as CSO at Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she established a robust gene therapy product portfolio in neurology and rare diseases. Earlier in her career, she spent more than 10 years at Eli Lilly, where she served in leadership roles of increasing responsibility and advanced multiple therapeutics into human clinical trials for Alzheimer’s disease and Parkinson’s disease. Dr. Shannon also previously held scientific leadership roles at Chugai/Roche Group and Merck.  Dr. Shannon earned her doctorate in Molecular Biology with Dr. Tom Shenk at Princeton University and conducted her postdoctoral research under Dr. Susumu Tonegawa (1987 Nobel Laureate) at the Massachusetts Institute of Technology.

Laura Sepp-Lorenzino, PhD, is Scientific Advisor, Executive Vice President and former Chief Scientific Officer at Intellia Therapeutics, a leading clinical-stage genome editing company developing novel, potentially curative medicines leveraging CRISPR-based technologies. Before joining Intellia, Laura was Vice President, Head of Nucleic Acid Therapies, and a member of the External Innovation team at Vertex Pharmaceuticals Incorporated, with previous positions as Vice President and Entrepreneur-in-Residence at Alnylam Pharmaceuticals, Inc., and Executive Director RNA Therapeutics at Merck & Co., Inc. In addition to her extensive experience in nucleic acid therapies, Laura has expertise in oncology drug discovery and development, which she acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as Assistant Attending Molecular Biologist at Memorial Sloan Kettering Cancer Center. She received her undergraduate degree in Biochemistry and Pharmacy from the University of Buenos Aires, Argentina, and her Master of Science and PhD in Biochemistry from New York University. Laura is a member of the Board of Directors of the American Society of Gene & Cell Therapy (ASGCT), Taysha Gene Therapies, Alliance for Regenerative Medicine, and Sail Biomedicines. She also sits on the Scientific Advisory Boards of Thermo Fisher Scientific; UK Medical Research Council, Nucleic Acid Therapy Accelerator; and Arsenal Capital Partners. Laura is a member of the Editorial Boards of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.